Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Autolus Therapeutics plc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 111
- −9 vs. Q1 2024
- Shares held
- 178.2M
- +2.50M (+1.4%) vs. Q1 2024
- Total value
- $620.0M
- −$500.6M (−44.7%) vs. Q1 2024
- New holders
- 15
- 39 more added
- Sold out
- 24
- 31 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 83 | $212.0M |
| Q1 2026 | 84 | $184.4M |
| Q4 2025 | 89 | $277.1M |
| Q3 2025 | 96 | $235.7M |
| Q2 2025 | 94 | $378.6M |
| Q1 2025 | 95 | $261.0M |
| Q4 2024 | 110 | $395.4M |
| Q3 2024 | 101 | $648.5M |
| Q2 2024 | 111 | $620.0M |
| Q1 2024 | 120 | $1.12B |
| Q4 2023 | 99 | $746.6M |
| Q3 2023 | 71 | $258.1M |
| Q2 2023 | 69 | $260.4M |
| Q1 2023 | 65 | $195.1M |
| Q4 2022 | 71 | $204.2M |
| Q3 2022 | 66 | $105.7M |
| Q2 2022 | 67 | $143.9M |
| Q1 2022 | 66 | $228.6M |
| Q4 2021 | 73 | $272.3M |
| Q3 2021 | 59 | $164.2M |
| Q2 2021 | 69 | $169.6M |
| Q1 2021 | 63 | $129.4M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Autolus Therapeutics plc; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 4,414,087 | $15.4M | 0.00% | −1,074,899−19.6% | Reduced |
| BlackRock Inc. | 4,436,102 | $15.4M | 0.00% | +380,182+9.4% | Added |
| Frazier Life Sciences Management, L.P. | 4,623,324 | $16.1M | 0.75% | 00.0% | Unchanged |
| Armistice Capital, LLC | 6,250,000 | $21.8M | 0.57% | +1,578,000+33.8% | Added |
| Polygon Management Ltd. | 8,000,000 | $27.8M | 8.63% | +474,318+6.3% | Added |
| FMR LLC | 12,295,167 | $42.8M | 0.00% | +3,278,777+36.4% | Added |
| Avoro Capital Advisors LLC | 12,345,678 | $43.0M | 0.57% | 00.0% | Unchanged |
| Deep Track Capital, LP | 15,272,172 | $53.1M | 1.59% | 00.0% | Unchanged |
| Wellington Management Group LLP | 17,889,834 | $62.3M | 0.01% | +7,126,833+66.2% | Added |
| Blackstone Group Inc. | 20,485,611 | $71.3M | 0.32% | 00.0% | Unchanged |
| Syncona Portfolio Ltd | 21,346,829 | $74.3M | 86.51% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 0 | $0 | 0.00% | −6,616,667−100.0% | Sold out |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −6,425,803−100.0% | Sold out |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −4,330,745−100.0% | Sold out |
| Lynx1 Capital Management LP | 0 | $0 | 0.00% | −1,390,160−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −492,000−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −429,152−100.0% | Sold out |
| Nomura Asset Management Co Ltd | 0 | $0 | 0.00% | −384,796−100.0% | Sold out |
| Harbor Capital Advisors, Inc. | 0 | $0 | 0.00% | −279,820−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −273,929−100.0% | Sold out |
| Voya Investment Management LLC | 0 | $0 | 0.00% | −205,225−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −155,857−100.0% | Sold out |
| EAM Global Investors LLC | 0 | $0 | 0.00% | −118,721−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −79,374−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −41,812−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −37,300−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −21,540−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −20,100−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −16,692−100.0% | Sold out |
| National Asset Management, Inc. | 0 | $0 | 0.00% | −17,000−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −3,100−100.0% | Sold out |
| Carmichael Hill & Associates, Inc. | 0 | $0 | 0.00% | −254−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −160−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −17−100.0% | Sold out |